Working... Menu

Anetumab Ravtansine With Nivolumab, Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Mesothelin Positive Advanced Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03816358
Recruitment Status : Suspended (Other - Validation of Assay)
First Posted : January 25, 2019
Last Update Posted : April 17, 2019
Information provided by (Responsible Party):
National Cancer Institute (NCI)

No Study Results Posted on for this Study
  Recruitment Status : Suspended
  Estimated Primary Completion Date : April 30, 2021
  Estimated Study Completion Date : April 30, 2021